Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Charito Love
• Collaborator: NCM USA
• Treatments: Edotreotide; Octreotide

Criteria

Inclusion Criteria:

• Signed informed consent.

• Patients of either gender, aged ≥18 years.

• Karnofsky status ≥60.

• Life expectancy of at least 12 weeks.

• Histologically and/or clinically confirmed and/or suspicious of NET.

• A diagnostic CT or MRI of the tumour region or suspected area within the previous 12 weeks prior to dosing day is available.

• Somatostatin-analogue scintigraphy scan with result (positive or negative) within the last 12 weeks.

• Recent Blood test results up to 4-6 weeks as follows:

1. White Blood Cell (WBC): >2*109/L

2. Haemoglobin: >8.0g/Dl

3. Platelets: >50x109/L

4. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline phosphatase (AP) each less than, or equal to, 5 times its Upper Limit of Normal (ULN)

5. Bilirubin less than, or equal to, three times its ULN

• Serum creatinine: within normal range or <120μmol/L for patients aged 60 years or older.

• Negative pregnancy test in women capable of child-bearing.

Exclusion Criteria:

• Known hypersensitivity to Gallium 68, DOTATOC or to any of the excipients of 68Ga-DOTATOC.

• Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (Long Acting Release) (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is on Sandostatin® LAR a wash-out phase of 28 days is required before the injection of the study drug.

• Pregnant or breast-feeding women.

• Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.